Home/Stacks/Growth Hormone Axis Stack
GROWTH STACK

Growth Hormone Axis Stack

Ipamorelin + CJC-1295 — the GHRP + GHRH pairing users research for physiologic GH pulse restoration.

Educational overview only — not medical advice. No compound in this stack is presented as a treatment for any condition. Any protocol decision is a conversation with your licensed healthcare provider.

About This Stack

The GH Axis Stack combines two GH-stimulating compounds that act on different receptors: Ipamorelin (a GHRP, ghrelin-receptor agonist) and CJC-1295 (a GHRH analog). The pairing is pharmacologically synergistic — two distinct upstream signals converging on the same pituitary output.

Users research this combination for endogenous IGF-1 elevation, body composition, and recovery. Unlike exogenous HGH, the GHRP + GHRH approach preserves the pituitary's native pulsatile release and negative-feedback loops, which is why many in the community prefer it for long-term work.

No compound here is a treatment for growth-hormone deficiency. Clinical GH deficiency is diagnosed and managed by an endocrinologist, and this stack is not a substitute for that pathway.

Why These Compounds Are Researched Together

Ipamorelin binds the GHS-receptor (ghrelin receptor), driving a clean GH pulse without significant cortisol or prolactin elevation. CJC-1295 (no-DAC) binds the GHRH receptor. The two receptors sum their output — the same pituitary cell receives both signals and releases more GH than either signal alone. This is the textbook pharmacology of GHRP + GHRH synergy.

Compounds in the Growth Hormone Axis Stack

IpamorelinGHRP
Ipamorelin
Ghrelin-receptor agonist — clean GH pulse, minimal cortisol/prolactin spillover.
CJC-1295GHRH
CJC-1295 (no DAC)
GHRH-receptor agonist — different receptor, synergistic output with ipamorelin.

Biomarkers Users Commonly Track

When running a stack like this, these biomarkers let users see how the compounds perform in context. Trended across draws, they reveal whether the stack is actually moving the markers it should — or producing unintended shifts that warrant a provider conversation.

GROWTH
IGF-1
Primary downstream marker of GH activity — the key tracking biomarker for any GH-axis protocol.
METABOLIC
HbA1c
GH elevation can affect insulin sensitivity — worth watching on longer cycles.
METABOLIC
Fasting Insulin
Fasting insulin catches insulin-resistance drift earlier than HbA1c.
METABOLIC
Fasting Glucose
Part of the metabolic panel to watch alongside IGF-1 on any GH protocol.

Typical Cycle

Community cycles typically run 8–16 weeks with structured breaks. Any cycling decision is a conversation with a licensed clinician who can monitor IGF-1 response.

What to Discuss With Your Provider

GH-axis manipulation has metabolic consequences (insulin sensitivity, IGF-1 exposure long-term). A provider should monitor IGF-1, fasting insulin, and metabolic markers at baseline, 6 weeks, and quarterly during use.

Related Stacks

LONGEVITY
Longevity Core Stack
Epithalon + BPC-157 + GHK-Cu — the foundational long-cycle combination users research for cellular aging and systemic repair.
GROWTH
Hollywood Body Composition Stack
Tesamorelin + Ipamorelin — the GHRH + GHRP body-composition combination researched by high-performance users.
Track the Growth Hormone Axis Stack against your labs.

Log every compound in the stack, upload your lab PDFs, and chart the biomarkers on this page across every draw. StackAI reads the panel in context of what you’re running.

Start tracking free →
Compliance notice: This page is informational and educational only. MyProtocolStack does not provide medical advice, diagnosis, or treatment. All references to compounds describe what users research and typically discuss with their clinician — not endorsements, prescriptions, or treatment recommendations. Research-stage compounds discussed are not FDA-approved unless specifically noted. Any protocol decision requires a licensed healthcare provider.